EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

The sponsor-proxy model: Bridging basic science discovery and investigator-initiated clinical trials

Xin Liu iD, Doris Shank, Junxuan Lü, Monika Joshi

Journal of Clinical and Translational Science · 2026 · 10 (1)

DOI: 10.1017/cts.2026.10782 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical and Translational Science, online erschienen am 24.06.2026. Verfasst von Xin Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, 17033, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Translating academic discoveries into clinical investigation remains a major barrier in translational science, particularly when investigators lack the regulatory infrastructure required to sponsor clinical trials. These challenges are especially pronounced for natural product therapeutics, which often lack commercial sponsorship despite promising preclinical evidence. The Penn State Cancer Institute established an Investigator-Initiated Trial Sponsor Support Unit (SSU) to facilitate investigator-initiated trials and support progression toward National Cancer Institute designation. We describe a translational science case study of a Sponsor-Proxy operational model in which a centralized institutional unit performs sponsor-level regulatory and trial infrastructure functions while investigators retain scientific and clinical leadership. Two National Institutes of Health-funded trials evaluating Angelica gigas Nakai extract (INM176) illustrate this framework. The SSU authored regulatory documentation including Investigator’s Brochures, coordinated Investigational New Drug submissions, and supported trial infrastructure while clinical teams maintained participant oversight. Both trials achieved activation timelines of 112 and 105 days, shorter than previously reported activation times and within National Cancer Institute operational benchmarks. Sponsor-level oversight continued throughout trial conduct, including regulatory reporting, safety monitoring, and protocol amendment support. This case study demonstrates how centralized institutional expertise can overcome sponsor-level barriers and enable translation of basic science discoveries into investigator-initiated early-phase clinical trials.

Schlagwörter

Stichwörter der Autor:innen

clinical trial infrastructureinvestigational new druginvestigator-initiated trialsregulatory sciencetranslational science

Autor:innen und Institutionen

  • Penn State Cancer Institute, Pennsylvania State University, Hershey, PA, 17033, USA.
  • Department of Neuroscience and Experimental Therapeutics, Penn State College of Medicine, Hershey, PA, 17033, USA.
  • Center for Cannabis and Natural Product Pharmaceutics, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA.
  • Department of Medicine, Division of Hematology and Oncology, Penn State College of Medicine, Hershey, PA, 17033, USA.

ORCID-Profile: Xin Liu

Förderung

  • NCI NIH HHS

Zitieren

APA

Liu, X., Shank, D., Lü, J., & Joshi, M. (2026). The sponsor-proxy model: Bridging basic science discovery and investigator-initiated clinical trials. Journal of Clinical and Translational Science, 10(1). https://doi.org/10.1017/cts.2026.10782

Vancouver

Liu X, Shank D, Lü J, Joshi M. The sponsor-proxy model: Bridging basic science discovery and investigator-initiated clinical trials. Journal of Clinical and Translational Science. 2026;10(1). doi:10.1017/cts.2026.10782

BibTeX
@article{Liu2026,
  author = {Liu, Xin and Shank, Doris and Lü, Junxuan and Joshi, Monika},
  title = {The sponsor-proxy model: Bridging basic science discovery and investigator-initiated clinical trials},
  journal = {Journal of Clinical and Translational Science},
  year = {2026},
  volume = {10},
  number = {1},
  doi = {10.1017/cts.2026.10782}
}
Kostenlos starten →